Fiche publication
Date publication
janvier 2025
Journal
ImmunoTargets and therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DUMORTIER Hélène
Tous les auteurs :
Gherardi L, Aubergeon L, Sayah M, Fauny JD, Dumortier H, Monneaux F
Lien Pubmed
Résumé
The co-inhibitory receptor B and T Lymphocyte Attenuator (BTLA) negatively regulates B and T cell activation. We have previously shown an altered BTLA expression by regulatory T cells and an impaired capacity of BTLA to inhibit CD4 T cell activation in lupus patients. In this study, we analyzed BTLA expression and function in the NZB/W lupus-mouse model and examined the therapeutic potential of BTLA targeting.
Mots clés
BTLA, inhibitory receptors, lupus mice, systemic lupus erythematosus
Référence
Immunotargets Ther. 2025 01 17;14:7-23
